Loading clinical trials...

Determination of the Glycemic Index of Products Varying in Levels of Refined and Whole Grain Corn | Clinical Trials | Clareo Health

COMPLETEDNA

Determination of the Glycemic Index of Products Varying in Levels of Refined and Whole Grain Corn

Determination of the Glycemic Index of Products Varying in Levels of Refined and Whole Grain Corn: a Randomized Controlled Trial in Healthy Participants

NCT07427654•PepsiCo Global R&D

View on ClinicalTrials.gov

Summary

Interest in identifying low GI foods and the food factors responsible for the low GI of foods has increased. Three corn products with varying levels of refined and whole grain corn will be compared to each other and to a dextrose control. It is hypothesized that higher levels of whole grain corn present in a food will decrease the rate of absorption and result in a lower postprandial glucose levels and glycemic index, and that the whole grain ingredient manufacturing process impacts whole grain ingredient benefits.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Adults aged 18-75 years, inclusive.
•BMI between 18.0 and 35.0 Kg/m2.
•Willing to abstain from unusual strenuous exercise and consuming alcoholic drinks for 24 hours before study days.
•Willing to refrain from smoking tobacco or marijuana for 12h before and during study visits.
•Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial.
•Understanding the study procedures \& willing to provide informed consent to participate in the study \& authorization to release relevant protected health information to the study investigator.
•Participants must be eligible to receive income in Canada and be covered by a health insurance plan such as OHIP.

Exclusion Criteria

•Self-reported pregnant or breastfeeding women.
•Known history of gastrointestinal disease (e.g., diverticulitis, Crohns disease, coeliac disease etc.), bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), or any condition which might, in the opinion of the medical director either: 1) make participation dangerous to the participant or to others, or 2) affect the results.
•Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the participant or to others, or 2) affect the results.
•Major trauma or surgical event within 3 months of screening.
•Unwillingness or inability to comply with the experimental procedures and to follow INQUIS health and safety policies.
•Known intolerance, sensitivity or allergy to test products.
•Participation in any clinical trial within the past 30 days (with the exception of routine GI testing of commonly consumed foods) or any PepsiCo sponsored trial within the past 3 months.

Locations (1)

INQUIS Clinical Research

Toronto, Ontario, Canada

Key Dates

Start Date

January 8, 2026

Primary Completion Date

March 12, 2026

Completion Date

March 12, 2026

Last Updated

March 16, 2026

Enrollment

ACTUAL participants

Conditions

Glycemic IndexGlycemic Load

Interventions

Corn snack containing 25 grams available carbohydrate

OTHER

Dextrose control

OTHER

The Effect of Consumption of Bread Types Made From Various Flours on Blood Glucose Fluctuations

NCT06288178

ObesityGlycemic Index+2 more

View study

COMPLETEDNA

Evaluation of the Glycemic Index in 4 Dairy Beverages.

NCT05204823

Glycemic IndexCognitive Performance

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Determination of the Glycemic Index of Products Varying in Levels of Refined and Whole Grain Corn

Inclusion Criteria

Exclusion Criteria

The Effect of Consumption of Bread Types Made From Various Flours on Blood Glucose Fluctuations

Evaluation of the Glycemic Index in 4 Dairy Beverages.

Glycemic Index of Italian Rice Varieties

Assessment of Glycemic Index of Different Dates

Effects of Hypocaloric Diets With Different Glycemic Loads on Pulse Wave Velocity